We Shouldn’t Give Up on Biosimilars—And Here Are the Data to Prove it

We Shouldn’t Give Up on Biosimilars—And Here Are the Data to Prove it

Source: 
Drug Channels
snippet: 

An interesting spat about biosimilars has emerged between two prominent policy-oriented physicians.

Dr. Peter Bach of Memorial Sloan Kettering argues that we should “throw in the towel” on biosimilars and begin regulating drug prices.

On the other side, Dr. Scott Gottlieb, a former FDA commissioner, argues that we shouldn’t give up on biosimilars, but instead make structural and legislative changes that would increase competition.